JACOB LABATUT: Open Payments
NPI 1003555624 · BATON ROUGE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$747 in 42 payments from 13 companies in 2025. Trend: 2023 $1,246 · 2024 $935 · 2025 $747
Food & beverage: $747
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $243 |
| Madrigal Pharmaceuticals | 4 | $96 |
| Janssen Biotech, Inc. | 4 | $87 |
| Ipsen Biopharmaceuticals, Inc | 3 | $55 |
| PFIZER INC. | 3 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $42 |
| Ardelyx, Inc. | 2 | $37 |
| Regeneron Healthcare Solutions, Inc. | 1 | $37 |
| Novo Nordisk Inc | 2 | $35 |
| Phathom Pharmaceuticals, Inc. | 3 | $23 |
Products named: REZDIFFRA, TREMFYA, LINZESS, RINVOQ, CREON, IQIRVO, IBSRELA, DUPIXENT.
Industry payments across LA — which companies pay providers there.
